CJC-1295 & Ipamorelin: A Technical Research Guide

A "CJC-1295 / Ipamorelin blend" is not a single molecule — it is a co-formulation of two distinct peptides supplied together in one vial or paired vials for parallel study:

• CJC-1295 — a 30-amino-acid, tetrasubstituted analog of growth hormone-releasing hormone (GHRH), built on the modified GRF(1–29) scaffold with a Drug Affinity Complex (DAC). Molecular formula C₁₅₂H₂₅₂N₄₄O₄₂; molecular weight ≈ 3647 Da. Without the DAC, the same modified GRF(1–29) core ("No-DAC") has a molecular weight of roughly 3358 Da.
• Ipamorelin — a pentapeptide, Aib-His-D-2Nal-D-Phe-Lys-NH₂ (Aib = aminoisobutyric acid). Molecular formula C₃₈H₄₉N₉O₁₀; molecular weight ≈ 711.9 Da. It is a selective agonist at the ghrelin receptor (GHS-R1a).

The two differ roughly five-fold in molecular weight and act on entirely different receptors — which is precisely why study designs pair them.

In published in-vitro work, CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, while Ipamorelin acts at the ghrelin receptor (GHS-R1a). The two receptors sit on complementary arms of the secretagogue axis, so co-application in cultured pituitary preparations is used to examine whether the pathways interact — for example, whether a GHRH-analog signal and a ghrelin-mimetic signal produce additive or synergistic growth hormone release in vitro.

Ipamorelin was developed specifically for receptor selectivity: early ghrelin-mimetics such as GHRP-6 are documented to interact with multiple receptor populations, whereas Ipamorelin's pentapeptide structure was optimized to limit off-target activity. That selectivity is a common rationale for choosing it over older ghrelin analogs in blend studies.

Because blends contain two peptides of very different mass and hydrophobicity, verification is done per component, not on the mixture as a whole. A certificate of analysis (CoA) for research-grade material should show:

• Reverse-phase HPLC (C18) — purity of at least 98% (research-grade suppliers commonly document 99%+) with a single dominant peak and a retention time matched against a reference standard. Truncated sequences, oxidized species, and diastereomers appear as secondary peaks, which is why peak shape matters as much as the headline purity number.
• Mass spectrometry (ESI-MS or MALDI-TOF) — a measured molecular weight confirming each sequence: ≈ 3647 Da for CJC-1295 and ≈ 712 Da for Ipamorelin. A mass spectrometry trace is the fastest way to catch a wrong or degraded sequence that HPLC alone cannot identify.
• Net peptide content — the percentage of the vial's gross weight that is actual peptide (counter-ions, residual moisture, and salts account for the difference). Content and purity are separate numbers and both should be reported.
• Lot number and batch traceability — every vial should be traceable to the CoA for its specific manufacturing lot.

Material without a per-lot CoA, or documented at less than ~98% purity, is generally not suitable for analytical reference work.

Both peptides are supplied as lyophilized (freeze-dried) powders in sealed sterile vials. In lyophilized form they are shelf-stable for extended periods when stored desiccated and protected from light; freezer storage (−20 °C) is the standard recommendation for long-term retention. Peptides are hygroscopic — allow the vial to reach room temperature before opening to prevent condensation from degrading the contents.

Once reconstituted for in-vitro use, solutions are substantially less stable than the dry powder. Solvent choice, pH, and temperature all affect degradation rate, and repeated freeze–thaw cycles should be avoided. Reconstitution concentration math is straightforward chemistry: for example, adding 1 mL of solvent to a 5 mg vial yields a 5 mg/mL solution; the concentration scales linearly with the volume added. Laboratories should follow their own validated handling protocols and use appropriate sterile technique and PPE.

What is a CJC-1295 / Ipamorelin blend?

A co-formulation of a GHRH analog (CJC-1295) and a ghrelin-mimetic pentapeptide (Ipamorelin), studied in vitro because the two act on complementary secretagogue receptor pathways.

How do the two compounds differ chemically?

CJC-1295 is a 30-amino-acid GHRH analog of ≈ 3647 Da; Ipamorelin is a pentapeptide of ≈ 712 Da that acts at the ghrelin receptor. They differ in mass, receptor target, and stability profile.

What purity standard should the blend meet?

≥98% by reverse-phase HPLC per component, confirmed by mass spectrometry, with net peptide content and a per-lot certificate of analysis.

How should it be stored?

Lyophilized, desiccated, protected from light; −20 °C for long-term storage. Avoid repeated freeze–thaw cycles once in solution.

Is it approved for human use?

No. These are research chemicals for in-vitro laboratory study only. They are not supplements and not approved for human consumption.